Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology
Onco-Innovations (ONNVF) has partnered with Dalton Pharma Services for the custom synthesis of a heavy labelled isotope of its exclusively-licensed PNKP inhibitor technology. The agreement, dated April 8, 2025, aims to advance IND-enabling animal model research through ADME studies.
The technology's effectiveness was previously demonstrated in a June 2021 University of Alberta study using PTEN-deficient colorectal cancer xenograft mice. The study showed that mice treated with the nanoparticle-encapsulated A83B4C63 (PNKP Inhibitor) achieved a median survival time of 60 days, compared to 23 days in untreated controls.
The technology enhances PNKP inhibitors' effectiveness while reducing impact on healthy tissues. This partnership with Dalton represents a important step toward generating necessary data for regulatory submissions and advancing the program toward clinical trials.
Onco-Innovations (ONNVF) ha stretto una collaborazione con Dalton Pharma Services per la sintesi personalizzata di un isotopo pesantemente marcato della sua tecnologia esclusiva di inibitori PNKP. L'accordo, datato 8 aprile 2025, mira a favorire la ricerca preclinica su modelli animali abilitanti l'IND attraverso studi ADME.
L'efficacia della tecnologia era stata già dimostrata in uno studio dell'Università di Alberta del giugno 2021, condotto su topi xenotrapiantati con cancro colorettale carenti di PTEN. Lo studio ha evidenziato che i topi trattati con A83B4C63 incapsulato in nanoparticelle (inibitore PNKP) hanno raggiunto un tempo mediano di sopravvivenza di 60 giorni, rispetto ai 23 giorni dei controlli non trattati.
Questa tecnologia potenzia l'efficacia degli inibitori PNKP riducendo al contempo l'impatto sui tessuti sani. La collaborazione con Dalton rappresenta un passo fondamentale per generare i dati necessari alle autorizzazioni regolatorie e per far avanzare il programma verso le sperimentazioni cliniche.
Onco-Innovations (ONNVF) se ha asociado con Dalton Pharma Services para la síntesis personalizada de un isótopo pesado marcado de su tecnología exclusiva de inhibidores PNKP. El acuerdo, fechado el 8 de abril de 2025, tiene como objetivo avanzar en la investigación preclínica en modelos animales habilitantes para IND mediante estudios ADME.
La eficacia de la tecnología fue demostrada previamente en un estudio de la Universidad de Alberta en junio de 2021, realizado en ratones xenoinjertados con cáncer colorrectal deficientes en PTEN. El estudio mostró que los ratones tratados con A83B4C63 encapsulado en nanopartículas (inhibidor de PNKP) alcanzaron un tiempo medio de supervivencia de 60 días, en comparación con 23 días en los controles no tratados.
La tecnología mejora la efectividad de los inhibidores PNKP mientras reduce el impacto en tejidos sanos. Esta alianza con Dalton representa un paso importante para generar los datos necesarios para las presentaciones regulatorias y avanzar el programa hacia ensayos clínicos.
Onco-Innovations (ONNVF)는 독점 라이선스된 PNKP 억제제 기술의 무거운 동위원소 표지 맞춤 합성을 위해 Dalton Pharma Services와 협력했습니다. 2025년 4월 8일자 계약은 ADME 연구를 통한 IND 승인 동물 모델 연구를 진전시키는 것을 목표로 합니다.
이 기술의 효과는 2021년 6월 앨버타 대학교 연구에서 PTEN 결핍 대장암 이식 마우스를 사용해 이미 입증되었습니다. 연구 결과, 나노입자에 캡슐화된 A83B4C63(PNKP 억제제)로 치료받은 마우스의 중앙 생존 기간이 60일로, 치료받지 않은 대조군의 23일과 비교되었습니다.
이 기술은 건강한 조직에 미치는 영향을 줄이면서 PNKP 억제제의 효과를 향상시킵니다. Dalton과의 이번 협력은 규제 제출에 필요한 데이터를 생성하고 임상 시험으로 프로그램을 진전시키는 중요한 단계입니다.
Onco-Innovations (ONNVF) s'est associé à Dalton Pharma Services pour la synthèse personnalisée d'un isotope lourd marqué de sa technologie exclusive d'inhibiteur PNKP sous licence. L'accord, daté du 8 avril 2025, vise à faire progresser la recherche sur des modèles animaux habilitants IND via des études ADME.
L'efficacité de la technologie avait déjà été démontrée dans une étude de l'Université de l'Alberta en juin 2021, utilisant des souris xénogreffées de cancer colorectal déficientes en PTEN. L'étude a montré que les souris traitées avec A83B4C63 encapsulé dans des nanoparticules (inhibiteur PNKP) ont atteint un temps médian de survie de 60 jours, contre 23 jours chez les témoins non traités.
La technologie améliore l'efficacité des inhibiteurs PNKP tout en réduisant l'impact sur les tissus sains. Ce partenariat avec Dalton représente une étape importante pour générer les données nécessaires aux soumissions réglementaires et faire avancer le programme vers les essais cliniques.
Onco-Innovations (ONNVF) hat eine Partnerschaft mit Dalton Pharma Services für die kundenspezifische Synthese eines schwer markierten Isotops seiner exklusiv lizenzierten PNKP-Inhibitor-Technologie geschlossen. Die Vereinbarung vom 8. April 2025 zielt darauf ab, die IND-fördernde Forschung an Tiermodellen durch ADME-Studien voranzutreiben.
Die Wirksamkeit der Technologie wurde bereits in einer Studie der University of Alberta im Juni 2021 an PTEN-defizienten kolorektalen Krebs-Xenotransplantat-Mäusen nachgewiesen. Die Studie zeigte, dass Mäuse, die mit nanopartikelverkapseltem A83B4C63 (PNKP-Inhibitor) behandelt wurden, eine medianes Überleben von 60 Tagen erreichten, verglichen mit 23 Tagen bei unbehandelten Kontrolltieren.
Die Technologie verbessert die Wirksamkeit von PNKP-Inhibitoren und reduziert gleichzeitig die Auswirkungen auf gesundes Gewebe. Die Partnerschaft mit Dalton stellt einen wichtigen Schritt dar, um die notwendigen Daten für behördliche Zulassungen zu generieren und das Programm in Richtung klinischer Studien voranzubringen.
- Significant survival improvement in preclinical studies (60 days vs 23 days)
- Technology demonstrates reduced toxicity and precise cancer cell targeting
- Progress toward IND-enabling development through ADME studies
- Strategic partnership secured with Dalton Pharma for isotope synthesis
- Still in early preclinical stage, requiring extensive testing before human trials
- Additional studies and regulatory approvals needed before commercialization
PNKP TechnologyShown in Past Study to Increase Survival Rate in Colorectal Cancer Bearing Mice
VANCOUVER, BC / ACCESS Newswire / April 17, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company")is pleased to announce that it has entered into an agreement with Dalton Pharma Services ("Dalton") dated April 8, 2025, for the custom synthesis of a heavy labelled isotope of its exclusively-licensed Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor (the "Technology"), based on a nanoparticle formulation of second-generation PNKP inhibitor, which when used as a monotherapeutic, was shown to increase the survival time of PTEN-deficient colorectal cancer tumor-bearing mice in a June 2021 study1 conducted by researchers at the University of Alberta ("Study"). This agreement with Dalton marks a critical step toward advancing IND-enabling animal model research, as the labelled compound will be used in upcoming ADME (Absorption, Distribution, Metabolism, and Excretion) studies.
The Study referenced above involved using a PTEN-deficient colorectal cancer (CRC) xenograft mouse model, intravenous administration of the nanoparticle-encapsulated A83B4C63 (the PNKP Inhibitor compound), which resulted in a noticeable increase in median survival. Mice treated with the A83B4C63 nano formulation showed a median survival time of 60 days, compared to 23 days in untreated controls, which highlights the therapeutic potential of A83B4C63 in PTEN-deficient CRC-bearing mice. Furthermore, the Technology was shown to enhance the effectiveness of PNKP inhibitors while reducing the impact on surrounding healthy tissues2, making it a promising avenue for advancing cancer therapies. Increasing survival rates is a critical objective in cancer research, and the success of the Technology in this Study illustrates the potential benefits of targeted nanoparticle delivery systems.
"Not only did the Study show that the Technology reduces toxicity, precisely targets cancer cells, and prevents them from regrowing, but it has also been shown to increase the survival rate in colorectal cancer-bearing mice. This is a substantial piece of information that reaffirms why we are so optimistic about the formula. As such, we are taking further steps to move the Technology toward clinical trials," said Thomas O'Shaughnessy, CEO of Onco-Innovations.
Signing the contract with Dalton represents an important step in pursuing the next phase of studies required to support IND-enabling development, as the Company believes that, absent such work, Onco would be unable to generate the necessary data to advance the program effectively. The ADME studies in mice are a foundational component of Onco's IND-enabling strategy, aimed at de-risking the compound ahead of future regulatory submissions. By building on strong preclinical efficacy data and advancing toward regulatory readiness, the Company is making meaningful progress in the clinical translation of its PNKP Technology.
About Dalton Pharma Services
Dalton Pharma Services, established in 1986 and based in Toronto, Canada, is a Health Canada-approved and FDA-inspected GMP contract provider of integrated chemistry, drug development, and manufacturing services to the pharmaceutical and biotechnology industries. With over 35 years of experience, Dalton offers a comprehensive range of in-house services, including drug discovery, flow chemistry, formulation and process development, custom synthesis, cGMP sterile fill/finish, cGMP API manufacturing, and dosage form manufacturing. This integration at a single location enhances adaptability, flexibility, and cost-effectiveness, accelerating drug discovery and development programs. Dalton's commitment to quality, speed, and flexibility has been recognized with CMO Leadership Awards from Life Science Leader in 2016, 2017, and 2018 across categories such as Quality, Reliability, Capabilities, Expertise, Compatibility, and Development.3
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, the Company's ability to submit and complete further clinical trials, the Company's ability to maintain reasonable commercial relations with contractual counterparties and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Company's technologies, the failure to complete further clinical trials, the failure to maintain reasonable commercial relations with contractual counterparties, the failure to receive regulatory approval in respect of the Company's technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
1. https://doi.org/10.1016/j.jconrel.2021.04.034
2. https://doi.org/10.1016/j.jconrel.2021.04.034
3. https://www.dalton.com/pharmaceutical-manufacturing
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What were the survival rate improvements shown by ONNVF's PNKP inhibitor technology in colorectal cancer mice?
How will the Dalton Pharma partnership advance ONNVF's PNKP technology development?
What are the key advantages of ONNVF's PNKP inhibitor technology in cancer treatment?
When did ONNVF sign the agreement with Dalton Pharma for PNKP isotope synthesis?
